Matt Abernethy has been tapped as CFO of Neurocrine Biosciences, which focuses on neurological and endocrine related disorders.
Abernethy has nearly 15 years of experience in the financial sector and investor relations with expertise in the healthcare industry. He joins Neurocrine from Zimmer Biomet, where he held various positions over the past nine years including vice president, investor relations, as well as treasurer and vice president of finance for the Americas and Global Product Engines.
In December 2016, Neurocrine announced that Timothy Coughlin would step down as CFO in 2017. Coughlin has remained with the company and will continue into 2018 to ease the transition.
Abernethy has a bachelor's degrees in accounting and business administration from Grace College and an MBA from the University of Chicago.
Neurocrine is a public company with a current market cap of $4.35 billion.